Santarus loads up on sales reps

Share this article:
Drug maker Santarus is bringing on 85 reps ahead of the launch of its ulcerative colitis drug Uceris.

The new hires are a mix of contract reps sourced from InVentiv Health and full-time Santarus reps. They will bring the launch force to 235 reps, along with 10 staff medical science liaisons. The company expects to connect with between 7,000 and 8,000 healthcare professionals, including rep-resistant primary care physicians along with endocrinologists. All will receive the same presentation -- CEO Gerry Proehl told MM&M that all reps, be they contract or in-house Santarus, have the same sales goals and pay incentives, and that all report to Santarus managers. The reason he gave was a simple one: all physicians should have a seamless experience.

What doctors should expect: iPad-equipped sales professionals with eight to ten years of pharmaceutical experience under their belts and leave-behinds by healthcare agency Harrison and Starr, which also handled some of the patient work.

Yet the pitch is not just about the drug's immediate target, of helping patients mid-flare-up. It also includes a pricing approach that aims to be in the managed care comfort zone. Proehl said the $1,235 for a month's supply is slightly below that of AstraZeneca's Entocort for Crohn's disease (the Santarus drug has a different indication, for ulcerative colitis). According to doctors Santarus has been talking to, the target patients – those in mid-flare – have symptoms between two to four times a year, but seek treatment about once or twice a year. The typical eight-week therapy would bring a patient's bill for the treatment to just under $5,000.

And although the drug is not yet on insurer formularies – the FDA approved it in January, long after formularies were set for the year – Proehl said that the drug is on insurers' minds, and that the company has been told that Uceris is being viewed as an interim drug patients can use before progressing to more expensive options, which can include higher-cost biologics or surgery. Proehl said he expects the drug to linger in the Tier 3 realm and possibly be tagged with a prior authorization requirement for the time being.
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...